NeuroTherapia announces completion of its Phase 2a Trial of a novel treatment for Alzheimer's Disease

Trial Designed to Demonstrate Target Engagement, Safety, and Pharmacokinetics CLEVELAND, April 7, 2026 /PRNewswire/ -- NeuroTherapia, Inc., a clinical-stage company focused on developing oral therapies for neurodegenerative diseases, has completed its Phase 2a clinical trial in...